1. Eisenhauer EA,
Therasse P,
Bogaerts J,
Schwartz LH,
Sargent D,
Ford R,
et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer.
2009 Jan;45(2):228-47.
2. Jaffe TA,
Wickersham NW,
Sullivan DC.
Quantitative imaging in oncology patients: Part 1,
radiology practice patterns at major U.S.
cancer centers.
AJR Am J Roentgenol.
2010 Jul;195(1):101-6.
3. Bird NC,
Mangnall D,
Majeed AW.
Biology of colorectal liver metastases: A review.
J Surg Oncol.
2006 Jul 1;94(1):68-80.
4. Liu LX,
Zhang WH,
Jiang HC.
Current treatment for liver metastases from colorectal cancer.
World J Gastroenterol.
2003 Feb;9(2):193-200.
5. Jakab Z,
editor.
The cancer burden in the European Union and the European Region: the current situation and a way forward.
WHO Informal Meeting of Health Ministers; 2010 4-5 July 2010; Brussels,
Belgium.
6. Kumar V.
Robbins and Cotran's pathologic basis of disease.
8th ed.
/ Vinay Kumar.
ed.
Philadelphia,
Pa.
; London: Saunders; 2010.
7. Sharma RA,
Van Hazel GA,
Morgan B,
Berry DP,
Blanshard K,
Price D,
et al.
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin,
fluorouracil,
and leucovorin chemotherapy.
J Clin Oncol.
2007 Mar 20;25(9):1099-106.
8. Muenzel D,
Engels HP,
Bruegel M,
Kehl V,
Rummeny EJ,
Metz S.
Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1.
Radiol Oncol.
2012 Mar;46(1):8-18.
9. Skougaard K,
McCullagh MJ,
Nielsen D,
Hendel HW,
Jensen BV,
Johannesen HH.
Observer variability in a phase II trial - assessing consistency in RECIST application.
Acta Oncol.
2012 Jul;51(6):774-80.